kaempferol-3-o-rutinoside and Multiple-Myeloma

kaempferol-3-o-rutinoside has been researched along with Multiple-Myeloma* in 1 studies

Other Studies

1 other study(ies) available for kaempferol-3-o-rutinoside and Multiple-Myeloma

ArticleYear
Bioactive metabolites from the leaves of Withania adpressa.
    Pharmaceutical biology, 2018, Volume: 56, Issue:1

    Withania (Solanaceae) species are known to be a rich source of withanolides, which have shown several biological properties.. To identify the compounds responsible for Withania adpressa Coss. antioxidant activity and further test them for their NF-κB inhibition and antiproliferative activity in multiple myeloma cells.. Compounds were obtained from the EtOAc extract of W. adpressa leaves. Structure elucidation was carried out mainly by 1D- and 2D-NMR, and mass spectrometry. Isolated compounds were tested in a dose-response for their in vitro NF-κB inhibition and antiproliferative activity in multiple myeloma cells after 5 and 72 h treatment, respectively.. The fractionation resulted in the isolation of a new glycowithanolide named wadpressine (5) together with withanolide F, withaferin A, coagulin L, and nicotiflorin. The latter showed a moderate ability to scavenge free radicals in DPPH (IC. One new glycowithanolide and four known compounds were isolated. Biological evaluation data gave further insight on the antitumor potential of withanolides for refractory cancers.

    Topics: Antioxidants; Cell Proliferation; Flavonoids; HEK293 Cells; Humans; Multiple Myeloma; NF-kappa B; Phenols; Plant Extracts; Plant Leaves; Withania; Withanolides

2018